Researchers around the world have continued breathing new life into a retracted study, which suggested that common antihypertensive medications were harmful in patients with COVID-19. From a report: Published online on May 1, 2020 in the New England Journal of Medicine, the study relied on Surgisphere data to claim an association between renin-angiotensin-aldosterone system (RAAS) inhibitor therapy and worse outcomes in hospitalized COVID-19 patients with cardiovascular disease. The journal retracted the paper due to concerns about fraudulent data on June 4, 2020 in a widely publicized move, but the study has continued to rack up citations — totaling at least 652 as of May 31, 2021, reported Todd Lee, MD, MPH, of McGill University in Montreal, and colleagues.
Just 17.6% of verified citations acknowledged or noted that the paper was retracted, according to their research letter published in JAMA Internal Medicine. In May of this year alone — 11 months after the article was retracted — it was referenced 21 times. “Our findings challenge authors, peer reviewers, journal editors, and academic institutions to do a better job of addressing the broader issues of ongoing citations of retracted scientific studies and protecting the integrity of the medical literature,” Lee’s group urged. The hypothesis that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) may be harmful in patients with COVID-19 has been floated since the early days of the pandemic, with the reasoning being that since the SARS-CoV-2 virus enters human cells through ACE2 receptors, upregulation of these receptors could put patients at risk.
of this story at Slashdot.
Source:: Slashdot